Abstract.
The study describes the protein kinase selectivity profile, as well as the binding mode of olomoucine II in the catalytic cleft of CDK2, as determined from cocrystal analysis. Apart from the main cell cycle-regulating kinase CDK2, olomoucine II exerts specificity for CDK7 and CDK9, with important functions in the regulation of RNA transcription. In vitro anticancer activity of the inhibitor in a panel of tumor cell lines shows a wide potency range with a slight preference for cells harboring a wild-type p53 gene. Cell-based assays confirmed activation of p53 protein levels and events leading to accumulation of p21WAF1. Additionally, in olomoucine II-treated cells, Mdm2 was found to form a complex with the ribosomal protein L11, which inhibits Mdm2 ubiquitin ligase function. We conclude that perturbations in RNA synthesis may lead to activation of p53 and that this contributes to the antiproliferative potency of cyclindependent kinase inhibitors.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 3 May 2005; received after revision 26 May 2005; accepted 8 June 2005
Rights and permissions
About this article
Cite this article
Kryštof, V., McNae, I.W., Walkinshaw, M.D. et al. Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. CMLS, Cell. Mol. Life Sci. 62, 1763–1771 (2005). https://doi.org/10.1007/s00018-005-5185-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-005-5185-1